176 related articles for article (PubMed ID: 32594366)
1. Identification of Recurrent TERT Promoter Mutations in Intrathyroid Thymic Carcinomas.
Tahara I; Oishi N; Mochizuki K; Oyama T; Miyata K; Miyauchi A; Hirokawa M; Katoh R; Kondo T
Endocr Pathol; 2020 Sep; 31(3):274-282. PubMed ID: 32594366
[TBL] [Abstract][Full Text] [Related]
2. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Tanaka A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1171-1175. PubMed ID: 30210064
[TBL] [Abstract][Full Text] [Related]
3. Intrathyroid thymic carcinoma: A clinicopathological analysis of 22 cases.
Gao Y; Pan Y; Luo Y; Cheng R; Zhai Q
Ann Diagn Pathol; 2023 Dec; 67():152221. PubMed ID: 37925863
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
5. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological Features of Intrathyroid Thymic Carcinoma].
Zheng ZG; Sun WY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Feb; 43(1):42-46. PubMed ID: 33663661
[TBL] [Abstract][Full Text] [Related]
8. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT.
Dettmer MS; Schmitt A; Steinert H; Capper D; Moch H; Komminoth P; Perren A
Endocr Relat Cancer; 2015 Jun; 22(3):419-29. PubMed ID: 25870252
[TBL] [Abstract][Full Text] [Related]
9. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
Jin A; Xu J; Wang Y
Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
[TBL] [Abstract][Full Text] [Related]
10. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma.
Gandolfi G; Ragazzi M; Frasoldati A; Piana S; Ciarrocchi A; Sancisi V
Eur J Endocrinol; 2015 Apr; 172(4):403-13. PubMed ID: 25583906
[TBL] [Abstract][Full Text] [Related]
12. Intrathyroid epithelial thymoma (ITET) and carcinoma showing thymus-like differentiation (CASTLE): CD5-positive neoplasms mimicking squamous cell carcinoma of the thyroid.
Kakudo K; Bai Y; Ozaki T; Homma K; Ito Y; Miyauchi A
Histol Histopathol; 2013 May; 28(5):543-56. PubMed ID: 23233417
[TBL] [Abstract][Full Text] [Related]
13. Intrathyroid thymic carcinoma: clinicopathological features and whole exome sequencing analysis.
Li J; Xiang R; Li Y; Liao Q; Liu Y
Virchows Arch; 2023 May; 482(5):813-822. PubMed ID: 37016248
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of immunohistochemical markers and thymic cortical microenvironmental cells in distinguishing thymic carcinoma from type b3 thymoma or lung squamous cell carcinoma.
Hayashi A; Fumon T; Miki Y; Sato H; Yoshino T; Takahashi K
J Clin Exp Hematop; 2013; 53(1):9-19. PubMed ID: 23801129
[TBL] [Abstract][Full Text] [Related]
15. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
16. Expression of
Masunaga A; Omatsu M; Kunimura T; Uematsu S; Kamio Y; Kitami A; Miyagi Y; Hiroshima K; Suzuki T
J Clin Pathol; 2017 Aug; 70(8):690-696. PubMed ID: 28119349
[TBL] [Abstract][Full Text] [Related]
17. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.
Bullock M; Ren Y; O'Neill C; Gill A; Aniss A; Sywak M; Sidhu S; Delbridge L; Learoyd D; de Vathaire F; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2016 Aug; 85(2):283-90. PubMed ID: 26667986
[TBL] [Abstract][Full Text] [Related]
19. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
20. TERT Promoter Mutation Spatial Heterogeneity in a Metastatic Follicular Thyroid Carcinoma: Implications for Clinical Work-Up.
Stenman A; Hysek M; Jatta K; Bränström R; Darai-Ramqvist E; Paulsson JO; Wang N; Larsson C; Zedenius J; Juhlin CC
Endocr Pathol; 2019 Sep; 30(3):246-248. PubMed ID: 31154561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]